Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06704009 · ClinicalTrials.gov registry record · Phase 1

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

A Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD, sponsored by NexThera Co..

Active
Registry status
Phase 1
Development phase
30
Enrollment target
4
Study locations

NCT06704009: Active Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD, sponsored by NexThera Co..

NCT06704009 is a Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD that is active but no longer recruiting, run by NexThera Co.. The registered enrollment target is 30 participants, below the 421-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06704009, a Phase 1 study of Wet Age-related Macular Degeneration and Wet AMD, is active but no longer recruiting, sponsored by NexThera Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
4
Study locations

Study Summary

Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)

Conditions Studied

Wet Age-related Macular Degeneration Wet AMD

Interventions

  • DRUG NT-101 Low Dose
  • DRUG NT-101 High Dose

Study Locations (4)

Maryland

  • Elman Retina Group - Rosedale

North Carolina

  • Duke Eye Center - Durham

Pennsylvania

  • Erie Retina Research - Erie

Texas

  • Texas Retina Associates - Dallas

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-11
Est. Completion 2026-03-30
Phase Phase 1
NexThera Co.

1 total trials

What the registry record for NCT06704009 still lists

NCT06704009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 421-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which NT-101 Low Dose is the first listed.

NCT06704009 reports a single indexed study location in Maryland, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06704009 about?

NCT06704009 is a clinical study titled "NT-101 Topical Ophthalmic Solution in Patients With Wet AMD". Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)

What is the current status of trial NCT06704009?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-11. Estimated completion is 2026-03-30.

What conditions does trial NCT06704009 study?

This clinical trial studies the following conditions: Wet Age-related Macular Degeneration, Wet AMD.

What interventions are being tested in trial NCT06704009?

The interventions under investigation include: NT-101 Low Dose (DRUG), NT-101 High Dose (DRUG).

Who is sponsoring clinical trial NCT06704009?

This trial is sponsored by NexThera Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06704009 being conducted?

This trial has 4 study locations across Maryland, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Wet Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06704009's enrollment target sits among peer trials

30 7th of 8 higher than 2 of 8 other Wet Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wet Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06704009, the US trial registry maintained by the National Library of Medicine. NCT06704009 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.